BM201 / InnoBM Pharma - LARVOL DELTA

Clinical efficacy and safety of BM201 intra-tumoral injection and radiotherapy in advanced solid tumors: Results from the phase I/IIT study. (ASCO 2026) - P=N/A, P1 | "R-ISV-BM201 has a manageable safety profile and has shown encouraging anti-tumor activity. A trigger systemic immune response would be expected when it is synergized with αPD-1 mAb."

Clinical • Metastases • Cardiovascular • Hematological Disorders • Hypertension • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Thrombocytopenia

Clinical efficacy, safety, and PK/PD from the first in human study of BM201, a TLR7/8 agonist (ESMO Asia 2024) - P1 | "Conclusions BM201 has a favorable safety profile and has shown encouraging anti-tumor activity in the dose escalation phase. Follow-up is still ongoing."

Clinical • P1 data • PK/PD data • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor